Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis

IF 8 2区医学 Q1 ENDOCRINOLOGY & METABOLISM

Obesity Reviews Pub Date : 2024-08-12 DOI:10.1111/obr.13811

Ali Esparham, Ali Mehri, Amin Dalili, Jesse Richards, Zhamak Khorgami

{"title":"Safety and efficacy of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with weight regain or insufficient weight loss after metabolic bariatric surgery: A systematic review and meta-analysis","authors":"Ali Esparham, Ali Mehri, Amin Dalili, Jesse Richards, Zhamak Khorgami","doi":"10.1111/obr.13811","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Introduction</h3>\n \n <p>Weight regain and insufficient weight loss are major challenges after metabolic bariatric surgery (MBS), affecting patients' comorbidities and quality of life. The current systematic review and meta-analysis aim to assess the efficacy and safety of GLP-1 receptor agonists (GLP-1 RA) in patients with weight regain or insufficient weight loss after MBS.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>A systematic search was conducted across PubMed, Embase, Scopus, and Web of Science databases to find the relevant studies.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>A total of 19 articles were included. The highest doses of liraglutide and semaglutide were 3 mg per day and 1 mg once weekly, respectively, in the included studies. The mean differences in weight and body mass index after treatment were −7.02 kg or 3.07 kg/m<sup>2</sup>, −8.65 or −5.22 kg/m<sup>2</sup>, and −6.99 kg or −3.09 kg/m<sup>2</sup> for treatment durations of ≤ 6 months, 6–12 months, and >12 months with liraglutide, respectively. Additionally, weekly semaglutide showed significantly greater weight loss compared to daily liraglutide, with a mean difference of 4.15 kg. Common complications included nausea (19.1%), constipation (8.6%), abdominal pain (3.7%), and vomiting (2.4%).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Using GLP-1 RA is a safe and effective treatment for weight regain and insufficient weight loss after MBS.</p>\n </section>\n </div>","PeriodicalId":216,"journal":{"name":"Obesity Reviews","volume":"25 11","pages":""},"PeriodicalIF":8.0000,"publicationDate":"2024-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Obesity Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/obr.13811","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Weight regain and insufficient weight loss are major challenges after metabolic bariatric surgery (MBS), affecting patients' comorbidities and quality of life. The current systematic review and meta-analysis aim to assess the efficacy and safety of GLP-1 receptor agonists (GLP-1 RA) in patients with weight regain or insufficient weight loss after MBS.

Methods

A systematic search was conducted across PubMed, Embase, Scopus, and Web of Science databases to find the relevant studies.

Results

A total of 19 articles were included. The highest doses of liraglutide and semaglutide were 3 mg per day and 1 mg once weekly, respectively, in the included studies. The mean differences in weight and body mass index after treatment were −7.02 kg or 3.07 kg/m², −8.65 or −5.22 kg/m², and −6.99 kg or −3.09 kg/m² for treatment durations of ≤ 6 months, 6–12 months, and >12 months with liraglutide, respectively. Additionally, weekly semaglutide showed significantly greater weight loss compared to daily liraglutide, with a mean difference of 4.15 kg. Common complications included nausea (19.1%), constipation (8.6%), abdominal pain (3.7%), and vomiting (2.4%).

Conclusion

Using GLP-1 RA is a safe and effective treatment for weight regain and insufficient weight loss after MBS.

查看原文本刊更多论文

胰高血糖素样肽-1（GLP-1）受体激动剂对代谢性减肥手术后体重反弹或体重减轻不足患者的安全性和疗效：系统综述与荟萃分析。

导言：体重反弹和体重减轻不足是代谢减肥手术（MBS）后面临的主要挑战，会影响患者的并发症和生活质量。本系统综述和荟萃分析旨在评估 GLP-1 受体激动剂（GLP-1 RA）对代谢性减肥术后体重反弹或体重减轻不足患者的疗效和安全性：方法：在 PubMed、Embase、Scopus 和 Web of Science 数据库中进行系统检索，以找到相关研究：结果：共纳入 19 篇文章。在纳入的研究中，利拉鲁肽和塞马鲁肽的最高剂量分别为每天 3 毫克和每周一次 1 毫克。利拉鲁肽治疗时间≤6个月、6-12个月和>12个月时，治疗后体重和体重指数的平均差异分别为-7.02千克或3.07千克/平方米、-8.65或-5.22千克/平方米和-6.99千克或-3.09千克/平方米。此外，与每日服用利拉鲁肽相比，每周服用塞马鲁肽的患者体重减轻幅度更大，平均差异为4.15千克。常见并发症包括恶心（19.1%）、便秘（8.6%）、腹痛（3.7%）和呕吐（2.4%）：结论：使用 GLP-1 RA 是治疗 MBS 后体重反弹和体重减轻不足的一种安全有效的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Obesity Reviews 医学-内分泌学与代谢

CiteScore

19.30

自引率

1.10%

发文量

130

审稿时长

1 months

期刊介绍： Obesity Reviews is a monthly journal publishing reviews on all disciplines related to obesity and its comorbidities. This includes basic and behavioral sciences, clinical treatment and outcomes, epidemiology, prevention and public health. The journal should, therefore, appeal to all professionals with an interest in obesity and its comorbidities. Review types may include systematic narrative reviews, quantitative meta-analyses and narrative reviews but all must offer new insights, critical or novel perspectives that will enhance the state of knowledge in the field. The editorial policy is to publish high quality peer-reviewed manuscripts that provide needed new insight into all aspects of obesity and its related comorbidities while minimizing the period between submission and publication.